WebinarsNew
Deep DiveNew
Explore Business Standard
Pharma Companies
Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a
Uzbekistan could offer enhanced subsidies and technology transfer incentives to encourage greater investment from Indian pharmaceutical companies, strengthening its position as a regional hub for pharmaceutical manufacturing and supply, Deputy Minister of Investment, Industry and Trade Shokhrukh Gulamov has said. "To expand local pharmaceutical manufacturing, Uzbekistan could adopt policies that simplify regulatory approvals and strengthen investment incentives. Streamlined licensing procedures, reduced bureaucratic barriers, and predictable regulatory timelines would make local production more attractive," he told PTI. Tax incentives and subsidies for technology transfer, industrial cluster participation, and export-oriented production could further encourage investment, he said. "Access to well-equipped industrial zones and joint ventures with local partners can accelerate production capacity while ensuring compliance with quality standards. Protection of intellectual property and
Pharma major Venus Remedies Limited on Saturday said it has received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for speciality oncology therapy -- Plerixafor. Plerixafor is a hematopoietic stem cell mobiliser used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant, the company said in a statement. This is the first marketing authorisation the company secured for Plerixafor anywhere in the world, it added. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and Venus Medicine Research Centre CEO, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in". "Plerixafor sits squarely in the kind of therapy class we are building our